BioWorld -- The team behind two recent successful start-ups, U3 Pharma AG and NeurImmune Therapeutics AG, is applying the lessons learned from those ventures to a new investment fund and has already completed its first deal, a CHF10 million (US$8.9 million) Series A round in start-up firm CT Atlantic AG.
